The Helio Solution to Early Cancer Detection
We harness the power of artificial intelligence and machine learning to predict the presence of cancer earlier.
Multi-Modal × Multi-Omics Integration
Helio's tests generate deeper, richer biological insights using machine-learning technology built on years of multi-modal and multi-omics research. Over the past ten years, our scientists have used artificial intelligence and machine learning to identify unique, proprietary methylation signatures, patterns of DNA methylation, that predict the presence of cancer as early as Stage I. We combine these methylation signatures with protein biomarkers to develop multi-analyte blood tests with greater sensitivity and specificity than current screening methods.
Our research continues to add more data types and features to our bioinformatics pipeline, capturing a wider array of signals and continuously improving our AI.
Optimizing DNA Methylation Capture with ECLIPSE™
Helio Genomics has developed a proprietary platform called ECLIPSE, which enables accurate, efficient detection of cell-free DNA methylation patterns from blood, identifying the unique biomarkers that signal cancer, using next-generation sequencing technology.
cfDNA Extraction
Cell-free DNA is extracted from a blood sample.
Library Prep & Enzymatic Conversion
The sample is prepared and enzymatically converted for analysis.
Hybridization & Capture
Target methylation regions are captured.
Pooling & Sequencing
Samples are pooled and sequenced using next-generation sequencing.
Watch the Video to Learn More
Circulating Tumor DNA Methylation Markers for Diagnosis and Prognosis of Hepatocellular Carcinoma
Published in Nature Materials.
Read the ArticleWhat's Next for Helio?
Helio is extending its platform beyond liver-cancer surveillance into recurrence, treatment monitoring and prognosis, while evaluating additional high-mortality cancers and pharma/companion-diagnostic applications. Our AI-based methods for early cancer detection are built on a robust research and development program, drawing on an extensive patient sample bank for validation.
Recurrence, Monitoring & Prognosis
Extending the HelioLiver platform beyond surveillance to recurrence, treatment monitoring and prognosis in HCC.
Additional High-Mortality Cancers
Evaluating the platform for earlier detection of other cancers with high mortality.
Pharma & Companion Diagnostics
Exploring pharma and companion-diagnostic applications of Helio’s multi-analyte approach.